Treatment of Geographic Atrophy With Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial

Wai T. Wong,Samuel Dresner,Farzin Forooghian,Tanya Glaser,Lauren E. Doss,M. Zhou,Denise Cunningham,Katherine Shimel,Molly Harrington,Keri Hammel,Catherine Cukras,Frederick L. Ferris,Emily Y. Chew

Treatment of Geographic Atrophy With Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial

2013

Wai T. Wong
Samuel Dresner
Farzin Forooghian
Tanya Glaser
Lauren E. Doss
M. Zhou
Denise Cunningham
Katherine Shimel
Molly Harrington
Keri Hammel
Catherine Cukras
Frederick L. Ferris
Emily Y. Chew

Purpose. To investigate the safety and effects of subconjunctival sirolimus, an mTOR inhibitor and immunosuppressive agent, for the treatment of geographic atrophy (GA).

Keywords:

Clinical trial
Sirolimus
Prospective cohort study
Retina
Drusen
Ophthalmoscopy
Visual acuity
Anatomy
Atrophy
Biology
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations